Recently, we reported that intracerebroventricularly and D609 (phosphatidylcholine-specific PLC inhibitor) (30, 100 and 300 nmol/animal, i.c.v.) had no effect. These results suggest the involvement of brain phosphatidylinositol-specific PLC and diacylglycerol lipase in the centrally administered histamine-induced activation of the adrenomedullary outflow in rats.
Introduction
Oxygenated metabolites of arachidonic acid such as prostaglandins and thromboxane A 2 have been demonstrated to act as neuromediator and/or neuromodulator in the brain actions including cardiovascular function (Chiu and Richardson, 1983; Wood et al., 1993; Zhang et al., 2003) and regulation of hormone secretion (Brooks et al., 1986; Bernardini et al., 1989; Reimsnider and Wood, 2006) .
Previously, we reported the involvement of brain arachidonic acid cascade in the centrally administered corticotropin-releasing factor-, arginine-vasopressin-and bombesin-induced elevation of plasma noradrenaline and adrenaline, since these responses were attenuated by central pretreatment with indomethacin, an inhibitor of cyclooxygenase, in rats (Okuma et al., 1997; Okada et al., 2003b) . In addition, centrally administered arachidonic acid elevated plasma levels of both catecholamines and these elevations were attenuated by central pretreatment with indomethacin in rats (Yokotani et al., 2000) . These results suggest the involvement of active metabolites of brain arachidonic acid in activation of the central sympatho-adrenomedullary outflow in rats.
Arachidonic acid has been shown to be released mainly by two different pathways: (1) phospholipase A 2 (PLA 2 ) hydrolyzes the sn-2 ester bond of membrane phospholipids, thereby releasing arachidonic acid (Irvine, 1982; Balsinde et al., 2002) ; (2) phospholipase C (PLC) cleaves the phosphodiester bond, resulting in the formation of diacylglycerol, which can be hydrolyzed by diacylglycerol lipase to yield arachidonic acid (Bell et al., 1979; Irvine, 1982; Moscat et al., 1986; Hou et al., 1996; Tang et al., 2006) . Previously, we reported that the brain PLA 2 is involved in the centrally administered melittin (PLA 2 activator)-induced elevation of plasma noradrenaline and adrenaline (Yokotani et al., 2000) , and that the brain PLCdiacylglycerol lipase pathway is involved in the centrally administered corticotropin-releasing factor-, argininevasopressin-and bombesin-induced elevation of plasma catecholamines in rats (Okada et al., 2003b; Shimizu et al., 2004 Shimizu et al., , 2005 .
Recently, we reported that central pretreatment with ketoprofen, an inhibitor of cyclooxygenase-1, attenuated the centrally administered histamine-induced elevation of plasma noradrenaline and adrenaline in rats (Shimizu et al., 2006) . In the present experiment, therefore, we aimed to clarify which phospholipase is involved in the histamineinduced elevation of plasma catecholamines using anesthetized rats. 6
Materials and methods

Experimental procedures
Male Wistar rats weighing about 350 g were maintained in an air-conditioned room at 22-24°C under a constant daynight rhythm for more than 2 weeks and given food (laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. Under urethane anesthesia (1.2 g/kg, i.p.), the femoral vein was cannulated for infusion of saline (1.2 ml/h), and the femoral artery was cannulated for collecting blood samples. After these procedures, the animal was placed in a stereotaxic apparatus, as shown in our previous papers (Yokotani et al., 1995; Shimizu et al., 2004) . The skull was drilled for intracerebroventricular administration of test substances using stainless-steel cannula (0.3 mm outer diameter). The stereotaxic coordinates of the tip of cannula were as follows (in mm): AP -0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, lateral from the midline; V, below the surface of the brain), according to the rat brain atlas (Paxinos and Watson, 1986) . Three hours were allowed to elapse before the application of histamine or the application of blocking All experiments were conducted in compliance with the guiding principles for the care and use of laboratory animals approved by the Kochi University.
Measurement of plasma catecholamines
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Blood samples (250 µl) were collected through an arterial catheter and were preserved on ice during experiments. Plasma were prepared immediately after the final sampling. Catecholamines in the plasma were extracted by the method of Anton and Sayre (1962) with a slight modification and were assayed electrochemically with high performance liquid chromatography (HPLC) (Shimizu et al., 2004) . Briefly, after centrifugation, the plasma (100 µl) was transferred to a centrifuge tube containing 30 mg of activated alumina, 2 ml of double deionized water, 1 ml of 1.5 M Tris Buffer (pH 8.6) containing 0.1 M disodium EDTA and 1 ng of 3,4-dihydroxybenzylamine as an internal standard. The tube was shaken for 10 min and the alumina was washed three times with 4 ml of ice-cold double deionized water. Then, catecholamines adsorbed onto the alumina were eluted with 300 µl of 4% acetic acid containing 0.1 mM disodium EDTA. A pump (EP-300: Eicom, Kyoto, Japan), a sample injector (Model-231XL; Gilson, Villiers-le-Bel, France) and an electrochemical detector (ECD-300: Eicom) equipped with a graphite electrode were used with HPLC. Analytical conditions were as follows: detector, +450 mV potential against a Ag/AgCl reference electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M NaH 2 PO 4 -Na 2 HPO 4 buffer (pH 6.0) containing 50 mg/l EDTA dihydrate, 0.75 g/l sodium 1-9 octanesulfonate and 15% methanol at a flow of 0.18 ml/min; injection volume, 40 µl. The amount of catecholamines in each sample was calculated using the peak height ratio relative to that of 3,4-dihydroxybenzylamine. By this assay, coefficients of variation for intra-and inter-assay were 3.0% and 3.7%, respectively, and 0.5 pg of noradrenaline and adrenaline were accurately determined.
Treatment of data and statistics
All values are expressed as the means±S.E.M. The data were analyzed by repeated-measure analysis of variance, followed by post-hoc analysis with the Bonferroni method. P values less than 0.05 were taken to indicate statistical significance.
Compounds
The following drugs were used: mepacrine ( 
Results
Effect of mepacrine (an inhibitor of PLA 2 ) on the centrally administered histamine-induced elevation of plasma catecholamines
Treatments with vehicle-1 (5 µl saline/animal, i.c.v.) and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and adrenaline ( 
Effect of U-73122 (an inhibitor of PLC) on the centrally administered histamine-induced elevation of plasma catecholamines
Treatments with vehicle-1 (2.5 µl DMF/animal, i.c.v.) and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and adrenaline (Fig. 2) . Pretreatment with U-73122 [100 nmol (46 µg)/animal, i.c.v.] also had no effect on the basal plasma levels of both catecholamines (Fig. 2) .
The histamine [27 nmol (Fig. 2) .
Effects of ET-18-OCH 3 (an inhibitor of phosphatidylinositol-specific PLC) and D609 (an inhibitor of phosphatidylcholine-specific PLC) on the centrally administered histamine-induced elevation of plasma catecholamines
Treatments with vehicle-1 (5 µl DMF or saline/animal, i.c.v.) and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and adrenaline ( Fig. 3A and B) . Pretreatment with ET-18-OCH 3 [30 nmol (15.7 µg)/animal, i.c.v.] and D609 [300 nmol (80 µg)/animal, i.c.v.] also had no effect on the basal plasma levels of both catecholamines (Fig. 3A and B) . (Fig. 3A) . On the other hand, the histamine-induced response was not influenced by D609
ET-18-OCH
[30, 100 and 300 nmol (8, 27 and 80 µg)/animal, i.c.v.] (Fig. 3B) .
Effect of RHC-80267 (an inhibitor of diacylglycerol lipase) on the centrally administered histamine-induced elevation of plasma catecholamines
Treatments with vehicle-1 (2.5 µl DMF/animal, i.c.v.) and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and adrenaline (Fig. 4) . Pretreatment with RHC-80267 [2.6 µmol (1000 µg)/animal, i.c.v.] also had no effect on the basal plasma levels of both catecholamines (Fig. 4) . Arachidonic acid may also be released through PLC-and diacylglycerol lipase-mediated pathway. This pathway was reported to be a source of arachidonic acid in human platelets (Bell et al., 1979) , murine macrophages (Moscat et al., 1986) , rat pancreatic acini (Hou et al. 1996 ) and rabbit aortae (Tang et al., 2006) . U-73122 has been shown to be a selective inhibitor of PLC in human platelets and polymorphonuclear neutrophils (Bleasdale et al., 1990; Smith et al., 1990) There are two types of PLCs: phosphatidylinositolspecific PLC and phosphatidylcholine-specific PLC.
Phosphatidylinositol-specific PLC hydrolyzes phosphatidylinositol phosphate(s) and phosphatidylcholinespecific PLC hydrolyzes phosphatidylcholine, thereby both generating diacylglycerol. The source of early production of diacylglycerol has been shown to be exclusively mediated by phosphatidylinositol-specific PLC, while phosphatidylcholine is the source of the sustained production of diacylglycerol by phosphatidylcholinespecific PLC (Diaz-Meco et al., 1989; Exton, 1994; Sbrissa et al., 1998; Rebecchi and Pentyala, 2000) . Histamine has been reported to contract cat duodenal smooth muscle cells by phosphatidylinositol-specific PLC-mediated mechanisms (Jeong et al., 2003) , and also to evoke Ca 2+ current in guinea-pig ileal smooth muscle cells by phosphatidylcholine-specific PLC-mediated mechanisms (Unno et al., 1998) . Then, we examined which PLC is involved in the centrally administered histamine-induced elevation of plasma catecholamines using ET-18-OCH 3 and D609. has been shown to selectively inhibit phosphatidylinositolspecific PLC with an IC 50 value of 9.6 µM in fibroblasts and adenocarcinoma cells (Powis et al., 1992) . D609 selectively inhibits phosphatidylcholine-specific PLC with an IC 50 value of 94 µM in human monocytic cells (Schutze et al., 1992) . Phospholipase D (PLD) has also been reported to be involved in the production of arachidonic acid. PLD-derived phosphatidate is subsequently transformed by phosphatidate phosphohydrolase into diacylglycerol, which can be further converted to arachidonic acid (Hodgkin et al., 1998; 18 Carrasco and Merida, 2007) . In fact, PLD-phosphatidate phosphohydrolase pathway was reported to be a source of diacylglycerol and arachidonic acid in rat osteoblast-like cells (Kaneki et al., 1998) and cultured vascular smooth muscle cells (Freeman, 2000) . However, the major substrate of PLD is phosphatidylcholine, which contains relatively little arachidonic acid in position 2 (Exton, 1994; Hodgkin et al., 1998; Carrasco and Merida, 2007) . On the other hand, 30-80% of total phosphatidylinositol is typically the sn-1-stearoyl-2-arachidonyl species (Hodgkin et al., 1998; Carrasco and Merida, 2007) . The actual values for noradrenaline and adrenaline at 0 min were 431±56 and 395±77 pg/ml in the group pretreated with vehicle-1 (n=10); 432±98 and 497±197 pg/ml in the group pretreated with mepacrine (1.1 µmol/animal) (n=5); 366±60
and 474±107 pg/ml in the group pretreated with mepacrine (2.2 µmol/animal) (n=14), respectively. were 335±34 and 211±38 pg/ml in the group pretreated with DMF (5 µl/animal) (n=13); 308±62 and 238±38 pg/ml in the
